Antiretroviral therapy has transformed HIV into a manageable chronic condition. But many people living with HIV face an unwelcome side effect: lipodystrophy - abnormal fat distribution that's not just cosmetic. That stubborn belly fat increases your cardiovascular risk, and it doesn't respond to diet and exercise the way normal fat does.
Written by — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
track_changesTesamorelinvaccinesGrowth Hormone
2Peptides in this guide
Week 1-4 → Long-TermTimeline
4Lifestyle areas
3Reality checks
radio_button_checked
Visceral Fat
Belly fat around organs that doesn't budge
person
Facial Wasting
Sunken cheeks and temples
favorite
Metabolic Risk
Increased cardiovascular complications
Understanding Lipodystrophy
Why HIV Treatment Changes Body Fat
HIV lipodystrophy syndrome involves two related but distinct problems. Lipoatrophy means loss of fat from certain areas - typically the face, arms, legs, and buttocks, leading to a gaunt appearance. Lipohypertrophy means accumulation of fat in other areas - especially deep in the abdomen (visceral fat), behind the neck ('buffalo hump'), and in the breasts.
This isn't just about appearance. Visceral abdominal fat is metabolically active tissue that increases insulin resistance, drives inflammation, and significantly raises cardiovascular risk. People with HIV already have elevated cardiovascular risk; lipodystrophy makes it worse.
format_quoteThe fat isn't just in the wrong place - it's the wrong kind of fat.
Older antiretroviral drugs (especially stavudine, zidovudine, and some protease inhibitors) are the main culprits. Newer regimens are less likely to cause lipodystrophy, but for those already affected, the changes can persist even after switching medications. That's where tesamorelin comes in - it's the only FDA-approved treatment specifically for this condition.
track_changes
Approved 2010
Tesamorelin
The FDA-Approved Solution
A growth hormone-releasing hormone (GHRH) analog that specifically targets and reduces visceral abdominal fat in people with HIV lipodystrophy.
Its role
Telling your body to burn the dangerous belly fat it's been hoarding
Typical range
0.1-0.2 mg daily
The bottom line
Tesamorelin is the only medication FDA-approved specifically for HIV-associated lipodystrophy. It reduces visceral fat by stimulating your body's natural growth hormone release, without the problems associated with giving growth hormone directly.
Investigational for HIV lipodystrophy (not FDA-approved for this indication)
Growth Hormone
The Direct Approach
Recombinant human growth hormone (rhGH) has been studied for HIV lipodystrophy but is not FDA-approved for this use and carries more risks than tesamorelin.
Its role
Directly replacing the hormone rather than stimulating its natural production
Typical range
Varies by protocol; typically lower doses than for GH deficiency
The bottom line
While growth hormone can reduce visceral fat, it's associated with more side effects than tesamorelin, including worsening glucose tolerance and joint pain. It's generally not preferred over tesamorelin for this condition.
Each peptide targets a different aspect of the condition. Together, they create a comprehensive approach.
01track_changesTesamorelinThe FDA-Approved SolutionTelling your body to burn the dangerous belly fat it's been hoarding
02vaccinesGrowth HormoneThe Direct ApproachDirectly replacing the hormone rather than stimulating its natural production
4 angles of attack
bolt
Stimulates GH Release
Tesamorelin mimics natural GHRH, prompting your pituitary gland to release growth hormone
Clinical trials show significant reduction in abdominal fat mass
monitor_heart
Preserves Metabolic Function
Unlike direct GH, tesamorelin has minimal effect on glucose tolerance
An honest breakdown based on research and clinical reports.
schedule
Phase 1 of 5
Week 1-4
Getting Started
What's happening inside
The medication is beginning to affect your GH/IGF-1 axis. Fat mobilization processes are starting, but visible changes are unlikely yet.
What you might notice
Getting used to daily injection routine
Possible injection site reactions (redness, itching) - usually mild
Some people notice subtle changes in how they feel
Labs may show increase in IGF-1 levels
warning Watch for
Injection site reactions are common but usually mild. Rotate sites within the abdomen. Avoid injecting into areas of lipodystrophy.
Realistic expectations
Focus on establishing the routine. Don't expect visible changes yet.
trending_up
Phase 2 of 5
Week 5-12
Early Response
What's happening inside
GH axis is responding. Fat mobilization is occurring. Some people begin noticing subtle changes in abdominal contour.
What you might notice
May notice waistband feeling slightly looser
Subtle reduction in belly firmness
Possible improvement in energy levels
Some people notice improved sleep
warning Watch for
Response assessment typically happens at week 12. If no measurable reduction in visceral fat, your provider may discuss whether to continue.
Realistic expectations
Changes are gradual. Some people notice improvements; others need more time.
auto_awesome
Phase 3 of 5
Month 4-6
Measurable Progress
What's happening inside
Clinical trial data shows significant trunk fat reduction by week 26. Changes should be measurable on imaging if not visually obvious.
What you might notice
Noticeable reduction in abdominal size for responders
Clothes fitting differently around the midsection
May see improvements in lipid profile
Potential reduction in liver fat on imaging
warning Watch for
Not everyone responds equally. About 50% of patients achieve at least 8% reduction in trunk fat.
Realistic expectations
Responders are seeing meaningful improvement. Non-responders may need to reassess treatment.
check_circle
Phase 4 of 5
Month 6-12
Optimization
What's happening inside
Maximum benefit typically achieved. Continued use maintains results. Without ongoing treatment, fat tends to reaccumulate.
What you might notice
Sustained reduction in visceral fat
Improved body image and quality of life
Metabolic parameters may improve
Benefits maintained with continued use
warning Watch for
Stopping treatment typically results in visceral fat reaccumulation within months.
Realistic expectations
This is a maintenance medication for most people - ongoing use needed to maintain benefits.
favorite
Phase 5 of 5
Long-Term
Ongoing Management
What's happening inside
Long-term studies show sustained benefit with continued use. Cardiovascular risk reduction from reduced visceral fat is an important ongoing benefit.
What you might notice
Continued visceral fat reduction maintained
Ongoing cardiovascular risk reduction
Quality of life improvements sustained
Regular monitoring continues
Realistic expectations
Tesamorelin is designed for long-term use in those who respond.
General guidelines based on research literature and clinical reports. Work with a healthcare provider experienced in peptide therapy to customize for your situation.
warningImportant: These are general guidelines. Don't self-prescribe based on internet articles. Work with a qualified healthcare provider.
medicationOriginal formulation (Egrifta): Must reconstitute before each use
medicationNew formulation (Egrifta WR): Ready-to-use, no reconstitution needed
medicationAssess response at 12 weeks - if no reduction in visceral fat, consider discontinuation
Timing considerations
scheduleEvening injection (before bed) aligns with natural GH surge during sleep
scheduleMorning injection also effective for convenience
scheduleConsistent timing is more important than specific time of day
scheduleAt least 30-60 minutes from food or other medications
repeat Cycling
Often used in longer cycles (12-16 weeks minimum) to see full benefits; can continue long-term
Growth Hormone · typical range
Varies by protocol; typically lower doses than for GH deficiency
Common protocols
medicationDoses used in studies vary considerably
medicationLower doses (1-2 mg/day) sometimes used to minimize side effects
medicationRequires careful monitoring of glucose and IGF-1 levels
Timing considerations
scheduleTypically administered in the evening or before bed
scheduleSubcutaneous injection
scheduleConsistent timing important for stable levels
repeat Cycling
Varies; often used in limited courses due to side effects
Not FDA-approved for HIV lipodystrophy. Higher risk of glucose intolerance, edema, and arthralgias compared to tesamorelin.
Practical tips
vaccinesInjection basics
Inject into abdomen, avoiding areas of lipodystrophy or scarring
Rotate injection sites within the approved area
Original Egrifta requires reconstitution before each use - follow instructions carefully
Newer Egrifta WR formulation is ready-to-use
Let refrigerated medication sit at room temperature briefly before injection
ac_unitStorage
Store in refrigerator (36-46°F/2-8°C)
Protect from light
Original formulation: Reconstituted solution should be used immediately
Do not freeze
Check expiration dates
Peptides work best as part of a comprehensive approach.
fitness_center
Exercise
Complementing Treatment
While exercise alone can't eliminate HIV-associated visceral fat, it can enhance tesamorelin's effects and provide independent cardiovascular benefits.
The basics that matter
Aerobic exercise
Regular cardio (walking, cycling, swimming) improves cardiovascular fitness and helps with overall metabolic health.
Resistance training
Weight training builds lean mass, which improves metabolic rate and insulin sensitivity.
Consistency over intensity
Regular moderate exercise is more sustainable and effective than sporadic intense sessions.
Condition-specific tips
Exercise alone typically doesn't resolve HIV lipodystrophy, but supports overall health
Building muscle mass can help improve body composition ratios
Cardio exercise has independent cardiovascular benefits important for this population
Start gradually if you haven't been active - build up over time
nutrition
Nutrition
Fueling Mitochondria
Your mitochondria need specific nutrients to function. Chronic illness often depletes these.
The basics that matter
Anti-inflammatory eating
Focus on vegetables, quality proteins, healthy fats. Minimize sugar, processed foods, and seed oils.
Blood sugar stability
Wild blood sugar swings stress mitochondria. Eat protein and fat with every meal. Don't skip meals.
Hydration
Dehydration impairs cellular function. Add a pinch of sea salt to your water for electrolytes.
Condition-specific tips
Visceral fat is associated with insulin resistance - limiting refined carbs helps
Mediterranean-style eating patterns have good evidence for cardiovascular health
Diet alone won't resolve HIV lipodystrophy but supports overall treatment
Work with a dietitian familiar with HIV for personalized guidance
stethoscope
HIV Care
Comprehensive Management
Tesamorelin works best as part of comprehensive HIV care with viral suppression and attention to cardiovascular risk factors.
The basics that matter
Maintain viral suppression
Undetectable viral load remains the foundation of HIV care and supports overall health.
ART optimization
If on older regimens, discuss with your provider whether switching could help prevent further lipodystrophy.
Cardiovascular risk management
Address all modifiable risk factors: blood pressure, cholesterol, smoking, diabetes.
Condition-specific tips
Switching from older to newer ART regimens may prevent worsening but doesn't reverse existing lipodystrophy
Regular cardiovascular risk assessment is important in this population
Tesamorelin doesn't replace other interventions for cardiovascular risk
Coordination between HIV specialist and other providers is important
favorite
Mental Health
Addressing Body Image
Lipodystrophy affects more than physical health - the visible changes can significantly impact self-image, social interactions, and mental well-being.
The basics that matter
Acknowledge the impact
Body changes from lipodystrophy are real and distressing. These feelings are valid.
Seek support
Support groups, counseling, and mental health care are important parts of managing this condition.
Connect with others
Many people with HIV face similar challenges. Peer support can be valuable.
Condition-specific tips
Facial lipoatrophy can be particularly distressing and may benefit from fillers
Depression and anxiety are common and treatable
Visible improvements from tesamorelin often improve quality of life significantly
Don't hesitate to seek mental health support
What to keep in mind.
warning
Not for Facial Wasting
Tesamorelin specifically targets visceral abdominal fat. It does NOT treat facial lipoatrophy (facial wasting). Facial filling procedures are the treatment for that aspect of lipodystrophy.
science
Not Everyone Responds
About 50% of patients achieve significant trunk fat reduction. If you don't respond by 12 weeks, continued treatment may not be beneficial. Response should be assessed.
repeat
Benefits Reverse Without Treatment
Visceral fat typically reaccumulates within months of stopping tesamorelin. This is a long-term treatment for most people who respond.
This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before starting any new treatment.
Evening injection (before bed) aligns with natural GH surge during sleep
Growth Hormone
The Direct Approach
Varies by protocol; typically lower doses than for GH deficiency
Typically administered in the evening or before bed
Early wins to watch
trending_upInjection routine established
trending_upPossible subtle energy improvements
trending_upIGF-1 levels responding
trending_upNo significant side effects
Support stack
Heart-healthy diet
Regular exercise (cardio + strength)
Cardiovascular risk management
ART optimization
Mental health support
Lifestyle priorities
1Consistent daily injection
2Regular physical activity
3Heart-healthy nutrition
4Comprehensive HIV care
5Cardiovascular risk factor management
HIV lipodystrophy is a real medical condition, not just a cosmetic concern. The excess visceral fat increases your cardiovascular risk in a population already at elevated risk. Tesamorelin offers a targeted, FDA-approved approach to reducing this dangerous fat.
Work closely with your HIV care team to integrate tesamorelin into your overall health management. It's one important tool in maintaining your health and quality of life while living with HIV.
0.1-0.2 mg dailyTesamorelin · typical range in this guide